The Human Host-Defense Peptide Cathelicidin LL-37 is a Nanomolar Inhibitor of Amyloid Self-Assembly of Islet Amyloid Polypeptide (IAPP).
Armiento. Valentina V; Hille. Kathleen K; Naltsas. Denise D; Lin. Jennifer S JS; Barron. Annelise E AE; Kapurniotu. Aphrodite A
Key Findings
- LL‑37 binds IAPP with nanomolar strength.
- The peptide blocks IAPP amyloid self‑assembly in vitro.
- LL‑37 reduces IAPP‑induced pancreatic beta‑cell damage in cell culture.
Practical Outcomes
- At this stage the work is purely laboratory‑based, so there’s no direct protocol you can follow today. It does hint that boosting LL‑37 levels (for example, via vitamin D, which naturally raises cathelicidin) might someday be explored for diabetes prevention, but more research and human trials are needed before any supplementation or dosing advice can be given.
Summary
Scientists found that the natural human peptide LL‑37 can stick to the hormone IAPP, which normally clumps together in the pancreas and harms insulin‑producing cells in type‑2 diabetes. In lab tests, LL‑37 stopped these clumps from forming and protected the cells, suggesting it might help guard against diabetes‑related damage.
Abstract
Amyloid self-assembly of islet amyloid polypeptide (IAPP) is linked to pancreatic inflammation, β-cell degeneration, and the pathogenesis of type 2 diabetes (T2D). The multifunctional host-defence peptides (HDPs) cathelicidins play crucial roles in inflammation. Here, we show that the antimicrobial and immunomodulatory polypeptide human cathelicidin LL-37 binds IAPP with nanomolar affinity and effectively suppresses its amyloid self-assembly and related pancreatic β-cell damage in vitro. In addition, we identify key LL-37 segments that mediate its interaction with IAPP. Our results suggest a possible protective role for LL-37 in T2D pathogenesis and offer a molecular basis for the design of LL-37-derived peptides that combine antimicrobial, immunomodulatory, and T2D-related anti-amyloid functions as promising candidates for multifunctional drugs.
Study Information
pubmed
2020
2020-04-30T00:00:00.000Z
10.1002/anie.202000148
28
37